Can a drug developed for sickle cell anemia mitigate lung damage in patients with COVID-19?
Scientists around the globe are working to identify approved and investigational drugs that can be repurposed to treat COVID-19.
May 13, 2020
0
3
Scientists around the globe are working to identify approved and investigational drugs that can be repurposed to treat COVID-19.
May 13, 2020
0
3
(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.
Mar 27, 2012
0
0
Although they have an important impact on children's health and education, school-based deworming programmes have a limited impact on the level of infection in the wider community, according to a mathematical modeling study ...
Feb 28, 2013
0
0
New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.
Aug 8, 2013
0
0
The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) for pediatric patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Aug 29, 2022
0
13
Treatment for painful episodes of blood vessel obstruction in sickle cell anemia is currently limited to controlling pain, but an investigational therapy might be able to interfere with the underlying cause of these events, ...
Mar 3, 2015
0
13
Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.
Sep 4, 2012
0
0
(HealthDay)—Anemia is independently associated with high platelet reactivity (HPR) and is associated with all-cause mortality and major bleeding after percutaneous coronary intervention with drug-eluting stents, according ...
Jun 9, 2016
0
3
(HealthDay)—Artesunate, a drug used in the treatment of severe malaria, may or may not be associated with hemolytic anemia, so the U.S. Centers for Disease Control and Prevention recommends close monitoring of patients ...
Jan 11, 2013
0
0
(HealthDay)—Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.
Apr 11, 2016
0
0